Asymchem Laboratories (Tianjin) Co., Ltd. (6821.HK)
HKD 57.35
(4.08%)
HKD 57.35
(4.08%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.02 Billion CNY | -24.92% |
| 2022 | 4.07 Billion CNY | 180.89% |
| 2021 | 1.41 Billion CNY | 44.43% |
| 2020 | 973.68 Million CNY | 29.35% |
| 2019 | 746.58 Million CNY | 37.33% |
| 2018 | 565.46 Million CNY | 9.56% |
| 2017 | 495.29 Million CNY | 28.29% |
| 2016 | 394.74 Million CNY | 56.6% |
| 2015 | 254.65 Million CNY | 34.29% |
| 2014 | 183.69 Million CNY | 29.2% |
| 2013 | 145.61 Million CNY | 38.19% |
| 2012 | 104 Million CNY | -1.39% |
| 2011 | 105.13 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 286.48 Million CNY | 102.65% |
| 2024 Q2 | 237.93 Million CNY | -19.41% |
| 2024 Q3 | 227.66 Million CNY | -4.32% |
| 2023 Q2 | 1.21 Billion CNY | 73.79% |
| 2023 FY | - CNY | -24.92% |
| 2023 Q4 | 83.67 Million CNY | -85.23% |
| 2023 Q3 | 566.57 Million CNY | -53.36% |
| 2023 Q1 | 699.02 Million CNY | 18.65% |
| 2022 Q3 | 1.08 Billion CNY | -24.87% |
| 2022 FY | - CNY | 180.89% |
| 2022 Q4 | 589.17 Million CNY | -45.53% |
| 2022 Q2 | 1.43 Billion CNY | 147.95% |
| 2022 Q1 | 580.63 Million CNY | 32.7% |
| 2021 Q1 | 160.95 Million CNY | -36.04% |
| 2021 Q4 | 437.56 Million CNY | 41.43% |
| 2021 FY | - CNY | 44.43% |
| 2021 Q3 | 309.38 Million CNY | -1.33% |
| 2021 Q2 | 313.54 Million CNY | 94.81% |
| 2020 Q1 | 103.07 Million CNY | -53.13% |
| 2020 Q2 | 281.42 Million CNY | 173.03% |
| 2020 FY | - CNY | 29.35% |
| 2020 Q3 | 217.86 Million CNY | -22.59% |
| 2020 Q4 | 251.63 Million CNY | 15.5% |
| 2019 Q3 | 165.37 Million CNY | 21.48% |
| 2019 Q1 | 107.53 Million CNY | -43.65% |
| 2019 Q2 | 136.13 Million CNY | 26.6% |
| 2019 FY | - CNY | 37.33% |
| 2019 Q4 | 219.93 Million CNY | 32.99% |
| 2018 Q1 | 104.93 Million CNY | -26.85% |
| 2018 FY | - CNY | 9.56% |
| 2018 Q4 | 190.82 Million CNY | 127.1% |
| 2018 Q3 | 84.02 Million CNY | 29.61% |
| 2018 Q2 | 64.83 Million CNY | -38.22% |
| 2017 Q2 | 92.6 Million CNY | 28.33% |
| 2017 FY | - CNY | 28.29% |
| 2017 Q4 | 143.44 Million CNY | 25.57% |
| 2017 Q3 | 114.23 Million CNY | 23.37% |
| 2017 Q1 | 72.15 Million CNY | -19.07% |
| 2016 Q1 | 54.58 Million CNY | -47.2% |
| 2016 FY | - CNY | 56.6% |
| 2016 Q4 | 89.15 Million CNY | -28.86% |
| 2016 Q3 | 125.31 Million CNY | 68.36% |
| 2016 Q2 | 74.43 Million CNY | 36.37% |
| 2015 Q3 | 28.32 Million CNY | 0.0% |
| 2015 Q4 | 103.38 Million CNY | 265.05% |
| 2015 FY | - CNY | 34.29% |
| 2014 FY | - CNY | 29.2% |
| 2013 FY | - CNY | 38.19% |
| 2012 FY | - CNY | -1.39% |
| 2011 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | -3217.824% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | -521.818% |